From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Cancer J. 2020 May/Jun;26(3):269-277. doi: 10.1097/PPO.0000000000000445.
The promise of immunotherapy has shone brightly for decades in hematologic malignancies and specifically in non-Hodgkin lymphoma. The last decade has witnessed the emergence of completely novel forms of immunotherapy, including immune checkpoint blockade, bispecific antibodies, and chimeric antigen receptor T cells. These treatments have shown phenomenal, and in some cases possibly curative, successes in various relapsed/refractory lymphomas. This review summarizes the most notable successes and promising findings as well as some of the attendant failures. These treatments will doubtlessly transform the treatment paradigms across many lymphoma subtypes. Yet, only if we can better understand their mechanisms of action, toxicity, and resistance will be able to maximize their therapeutic benefit.
免疫疗法的承诺在几十年来一直在血液恶性肿瘤中闪耀光芒，特别是在非霍奇金淋巴瘤中。过去十年见证了完全新型免疫疗法的出现，包括免疫检查点阻断、双特异性抗体和嵌合抗原受体 T 细胞。这些治疗方法在各种复发/难治性淋巴瘤中取得了显著的、在某些情况下可能治愈的成功。这篇综述总结了最显著的成功和有前途的发现，以及一些伴随的失败。这些治疗方法无疑将改变许多淋巴瘤亚型的治疗模式。然而，只有我们能够更好地理解它们的作用机制、毒性和耐药性，才能最大限度地发挥它们的治疗效益。
